Skip to main content
Premium Trial:

Request an Annual Quote

David Agus, Mari Baker, David Brailler, John Doerr, Dana Mead, Sue Siegel, Carlos Camargo, Daniel Federman, Bruce Landon, Redonda Miller, Michael Nierenberg, Jeffrey Trent, David Botstein, Isaac Kohane, Nicholas Schork, Dietrich Stephan, Peggy Conrad, Eli

Navigenics said this week that it has formed its board of directors and advisory boards.
The board of directors includes David Agus, a company cofounder; Mari Baker, Navigenics’ president and CEO; David Brailer, chairman of Health Evolution Partners; John Doerr, a partner of Kleiner Perkins Caufield and Byers; Dana Mead, also a partner of Kleiner Perkins Caufield and Byers; and Sue Siegel, a partner of Mohr Davidow Ventures.
Agus also chairs the company’s clinical advisory board. He is the research director of the Louis Warschaw Prostate Cancer Center and director of the Spielberg Family Center for Applied Proteomics at Cedars-Sinai Medical Center.
Additional members of the clinical advisory board are Carlos Camargo, an emeritus clinical professor of medicine at Stanford University; Daniel Federman, a professor of medicine at Harvard Medical School; Bruce Landon, an associate professor of healthcare at Harvard Medical School and associate professor of medicine at Beth Israel Deaconess Medical Center; Redonda Miller, an associate professor of medicine at Johns Hopkins University; and Michael Nierenberg, medical director of Navigenics and emeritus clinical professor of medicine at Stanford University.
Jeffrey Trent, president and scientific director of the Translational Genomics Research Institute in Phoenix, chairs Navigenics’ scientific advisory board. Other SAB members are David Botstein, professor of genomics at Princeton University; Isaac Kohane, professor of pediatrics and health sciences as well as health sciences and technology at Harvard Medical School; Nicholas Schork, director of research at Scripps Genomic Medicine and professor of molecular and experimental medicine at the Scripps Research Institute; Dietrich Stephan, cofounder and chief science officer of Navigenics and until recently deputy director for discovery research at TGen.
Peggy Conrad is the chair of Navigenics’ genetic counseling task force. She is a practicing genetic counselor with more than 10 years' experience in hereditary cancer genetics. Additional members of the task force are Elissa Levin, genetics counseling program director at Navigenics; and Kelly Ormond, associate professor of genetics and director of the human genetics and genetic counseling graduate training program at Stanford.
Greg Simon chairs the policy and ethics task force. He is the president of FasterCures-The Center for Accelerating Medical Solutions. Other members of that task force are Rachel Grob, associate dean of graduate studies and director of the Child Development Institute at Sarah Lawrence College; Kathi Hanna, an analyst, writer, and editor specializing in biomedical research policy and previously research director and editorial consultant to President Clinton's National Bioethics Advisory Commission; and Paul Slovic, founder and president of Decision Research.


BioTrove has named Jeffrey Leathe as chief financial officer and has charged him with overseeing IT infrastructure development. Leathe has experience in both large public companies and in start-ups, BioTrove said. He formerly was at Apogent, Prime Computer, and at Congoleum Industries. He also is director and chairman of the audit committee for Bottomline Technologies and is a director of the Senator George J. Mitchell Research Scholarship Institute.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.